AstraZeneca extends its second contract with ImpediMed to use SOZO for tracking patient fluid volume.
IPD expects to generate more than AU$5.5 million in revenue across the trials.
The Company has received positive feedback on SOZO.
ImpediMed Limited (ASX.IPD) shares are gaining attention following the announcement related to the second contract extension and expansion of its SOZO Digital Health Platform used in clinical trials being conducted for AstraZeneca.
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
AstraZeneca Extends its Deal with ImpediMed
Key Takeaways:
ImpediMed Limited (ASX.IPD) shares are gaining attention following the announcement related to the second contract extension and expansion of its SOZO Digital Health Platform used in clinical trials being conducted for AstraZeneca.
Recent Latest News